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A wide range of clinical applications in regenerative medicine were opened decades ago with the discovery of adult stem cells.
Highly promising adult stem cells are mesenchymal stem/stromal cells derived from adipose tissue (ADSCs), primarily because
of their abundance and accessibility. These cells have multipotent properties and have been used extensively to carry out
autologous transplants. However, the biology of these cells is not entirely understood. Among other factors, the regeneration
capacity of these cells will depend on both their capacity of proliferation/differentiation and the robustness of the biochemical
pathways that allow them to survive under adverse conditions like those found in damaged tissues. The transcription factors,
such as Nanog and Sox2, have been described as playing an important role in stem cell proliferation and differentiation. Also,
the so-called longevity pathways, in which AMPK and SIRT1 proteins play a crucial role, are essential for cell homeostasis
under stressful situations. These pathways act by inhibiting the translation through downregulation of elongation factor-2
(eEF2). In order to deepen knowledge of mesenchymal stem cell biology and which factors are determinant in the final
therapeutic output, we evaluate in the present study the levels of all of these proteins in the ADSCs from humans and rats and
how these levels are affected by aging and the oxidative environment. Due to the effect of aging and oxidative stress, our results
suggest that before performing a cell therapy with ADSCs, several aspects reported in this study such as oxidative stress status
and proliferation and differentiation capacity should be assessed on these cells. This would allow us to know the robustness of
the transplanted cells and to predict the therapeutic result, especially in elder patients, where probably ADSCs do not carry out
their biological functions in an optimal way.
1. Introduction
Adipose-derived stem/stromal cells (ADSCs) have proven to
serve as an abundant, accessible, and rich source of mesenchy-
mal stem/stromal cells (MSCs) [1, 2]. These cells havemultipo-
tentproperties suitable for tissue engineering and regenerative
medicine applications, including potential restoration of
organ optimal functions that decline during aging [3, 4].
There is considerable evidence that deleterious molecular
complex changes happen in all organisms during aging [5, 6].
Those changes also impact the regenerative capabilities of
adult stem cells [7–10]. Although its causative role in aging
remains to be demonstrated, oxidative stress is closely related
to this process most of the time [11, 12]. Oxidative stress
represents an unbalanced situation in which reactive oxygen
species (ROS) generation exceeds antioxidant systems lead-
ing to tissue damage [11]. It is increasingly recognized that
only unregulated levels of ROS are harmful, while regulated
ROS production promotes essential signaling pathways,
which regulate cell functions such as cell proliferation, differ-
entiation, survival, and apoptosis [11, 13, 14].
Many aspects of stem cells (SCs) are affected by aging,
which can limit their clinical applications. For instance, the
number and quality of SCs decrease with donor age [15, 16]
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and affect the proliferation and differentiation potential both
in vitro and in vivo [15, 17]. Transcription factors such as
Nanog, Oct4, and Sox2 have been identified as essential
regulators of proliferation and differentiation in SCs [18,
19], and their importance has even been reported in MSCs
[20]. These transcription factors interact and regulate each
other with their own expression [21]. The core of this net-
work can also be deregulated during aging [20, 22], affecting
the process of differentiation such as adipogenesis and osteo-
genesis in ADSCs [15, 23].
In addition to the aforementioned transcription factors,
other proteins such as SIRT1 and AMP kinase (AMPK) have
been described as important in the proliferation and differen-
tiation capacity of stem cells. These proteins play an impor-
tant role in the longevity and the capacity of tissue
regeneration [24, 25]. AMPK is activated when the cellular
ATP levels fall. In order to restore energy levels, AMPK
inhibits anabolism (inhibits synthesis of proteins, cholesterol,
and glycogen) and stimulates catabolic reactions from glucose
and fatty acids during this energy stress. At the same time, it
stimulates the recycling of cellular components (autophagy)
[26]. SIRT1 is aNAD-dependent deacetylase withmany func-
tions in cellular metabolism, health, and aging [27], which is
activated by caloric restriction and promotes cell survival. In
fact, SIRT1 is able to decrease the levels of ROS by deacetylat-
ing and activating FOXO and PGC-1α [27].
Both AMPK and SIRT1 expression change with age and
under oxidative stress conditions [24, 28, 29]. AMPK and
SIRT1 have as target the elongation factor-2 (eEF2) [30,
31], which is the protein that moves the ribosome along the
mRNA in the translation process. eEF2 can be regulated by
multiple mechanisms [11, 32–34]. In general, those biochem-
ical pathways that promote longevity act by inhibiting the
translation through downregulation of eEF2 [30, 31].
Considering that (1) several proteins are involved in the
maintenance of the self-renewal state and differentiation
capacity of the stem cells, (2) these cells must perform their
repairing function in adverse conditions. In this work, we
evaluate some aspects of the biology of ADSCs that may
affect their therapeutic capacity and/or their survival capabil-
ities once they are transplanted into the site to be repaired.
Here, we present how aging and oxidative stress, induced
by cumene hydroperoxide (CH), can affect the viability and
number of ADSCs, the levels of several proteins involved in
the maintenance of the self-renewal state (Nanog and
Sox2), the differentiation capacity, and the survival pathways
(AMPK, SIRT1, and eEF2) in both rats and humans.
2. Material and Methods
2.1. Human Samples. 300ml of lipoaspirates was obtained
after liposuction from the abdominal region of twelve female
patients (body mass index between 24 and 29) that freely
volunteered with different ages ranging from 25 to 48 years
old (Table 1). Volunteers with pathologies were excluded.
Samples were obtained from different aesthetic clinics under
confidentiality and informed consent. All procedures were
performed based on the regulations established by the Ethical
Committee ofVirgen del RocíoHospital (Seville, Spain). Sam-
ples were stored at 4°C and processed within 24 h. The HeLa
cell line (Life Technologies Invitrogen, Inc., Paisley, UK) was
used as a human nonstem cell control for in vitro experiments
and used at the same passage time after thawing. Cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM;
Life Technologies Invitrogen, Inc., Paisley, UK), supple-
mented with 10% fetal bovine serum, 50U/ml penicillin G
sodium, 50U/ml streptomycin, and 2mM L-glutamine.
2.2. Experimental Animals. All experiments were carried out
according to the guidelines of the European Union Council
(Directive 2010/63/UE) and to the Spanish regulations (BOE
34/11370, RD 53/2013) that were approved by the Ethics
Committee of the University of Seville (# 19/03/2018/029).
Male Wistar rats (250-700 g) were kept at a constant temper-
ature of 22 ± 1°C and relative humidity of 60%, with a light-
dark cycle of 12 h and free access to food and water.
In order to study the effect of aging, three groups of four
animals each were used: 2-, 9-, and 24-month-old rats. To
evaluate the effect of oxidative stress, one-month-old rats
were divided randomly into three groups of five animals
each, which were intraperitoneally injected with NaCl 0.9%
(control) and 40 and 80mg/kg/day of CH, respectively, for
30 days [34, 35].
2.3. Rat Adipose Stromal Vascular Fraction Isolation. Animals
were anesthetized with ketamine/xylazine (100/12.5mg/kg).
Subcutaneous adipose tissue from the inguinal region was
obtained and weighted in sterile conditions. The tissue was
washed with sterile phosphate-buffered saline (PBS) and was
enzymatically processed by collagenase (Collagenase NB 4G,
Serva, Iceland, NY, USA) solution (0.9 units/ml) incubated
at 37°C for 150min on an orbital shaker. Then, an equal vol-
ume of “stop medium” (Dulbecco’s modified Eagle’s medium
(DMEM)) (Sigma-Aldrich, Saint Louis, MO, USA) with 20%
fetal bovine serum (FBS) (Sigma-Aldrich) was added; then,
samples were centrifuged at 600 × g for 10min at 4°C. The
pellet was resuspended in culture media (DMEM+10% FBS
+1% penicillin-streptomycin), and the cell suspension was
filtered through a 40μm pore-size filter to obtain the stromal
vascular fraction (SVF).
2.4. Human Adipose Stromal Vascular Fraction Isolation.
Lipoaspirates were washed with PBS and enzymatically proc-
essed by collagenase (Collagenase NB 4G, Serva, Iceland, NY,
USA) solution incubated (0.3 units/ml) at 37°C for 120min in
an orbital shaker. Then, an equal volume of “stop medium”
(DMEM) with 20% FBS was added and samples were centri-
fuged at 600 × g for 10min at 4°C. The pellet was resuspended
in DMEM+10% FBS+1% penicillin-streptomycin, and the
cell suspension was filtered through a 100μm pore-size filter.
This last step was repeated but using a 40μmpore-size filter to
obtain human SVF.
2.5. Rat and Human ADSC Isolation. In order to perform the
extraction of the ADSCs according to guidelines established
by the International Society for Cellular Therapy (ISCT),
we first performed a magnetic separation based on MACS©
technology (Magnetic Cell Sorting, Miltenyi Biotec, Bergisch
Gladbach, Germany). This procedure is based on the use of
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the so-called “microbeads” which are magnetic microparti-
cles associated with antibodies that specifically recognize
antigens on the surface of stem cells [36, 37]. The CD271
(low-affinity nerve growth factor receptor (LNGFR)) APC-
conjugated antibody (Miltenyi Biotec, Bergisch Gladbach,
Germany) with secondary anti-APC microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) was chosen to obtain
human ADSCs (hADSCs) [38–40]. Because the homologous
CD271 marker has not been described in rats, we used
CD90.1 (thymocyte differentiation antigen-1.1, a mouse
monoclonal antibody that reacts with rat CD90) microbead
antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) to
obtain rat ADSCs (rADSCs) [41, 42]. After magnetic separa-
tion, cells were centrifuged, resuspended, and cultured in
DMEM+10% FBS+1% penicillin-streptomycin for rADSCs
and StemMACS MSC expansion media (Miltenyi Biotec,
Bergisch Gladbach, Germany) for hADSCs. Finally, cells
were incubated and maintained in culture at 37°C in 5%
CO2. Because of the loss of pluripotency in hMSCs and
rADSCs during culture, we limited the expansion time to
four passages. Thus, all samples were five cell passages old
when assays were assessed.
2.6. Phenotyping Rat and Human ADSCs by Flow Cytometry.
To verify the presence of surface markers expressed by cells
such as ISCT suggests, we used a human MSC phenotype
kit (Miltenyi Biotec, Bergisch Gladbach, Germany) for
hADSCs, which contains the CD14-PerCP, CD20-PerCP,
CD34-PerCP, CD45-PerCP, CD73-APC, CD90-FITC, and
CD105-PE monoclonal antibodies. hADSCs were detached
from culture, and 1 × 105 cells were treated following the
manufacturer’s instructions. For rADSC phenotyping, we
used the monoclonal antibodies labeled with mouse anti-
CD34-PE (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), CD45-PE (BD Pharmingen, Dallas, TX, USA),
CD11b-PE (BioLegend, San Diego, CA, USA), and CD29-
APC and CD90.1-FITC (Miltenyi Biotec, Bergisch Gladbach,
Germany). The cytometry analysis was carried out in a FC500
Cytometer (Beckman Coulter, Pasadena, CA, USA), and the
data was analyzed using Summit 2.0 software. Voltage and
color compensations were previously set up.
2.7. Rat and Human ADSC Differentiation. The differentia-
tion capacity was assessed following the manufacturer’s
instructions for commercial differentiation kits. For rADSCs,
cells were cultured in a differentiation medium (StemXVivo
Osteogenic/Adipogenic Media-R&D Systems, Minneapolis,
MI, USA) with adipogenic or osteogenic supplements
contained in the kit. Adipocytes were detected by Oil Red
O (Sigma-Aldrich, Saint Louis, MO, USA) staining and
osteoblasts by NBT/BCIP (Sigma-Aldrich, Saint Louis, MO,
USA) staining. To differentiate into chondrocytes, 2:5 × 105
cells were cultured in DMEM/F-12 media (Sigma-Aldrich,
Saint Louis, MO, USA) plus chondrogenic supplements
(StemXVivo Chondrogenic Supplement-R&D Systems) in
the bottom of a 15ml conical tube. The cell pellet formed a
rounded ball approximately 1-2mm in diameter on the 3rd
day. On the 14-28th days, the pellet was fixed in 4% parafor-
maldehyde and cut into 10μm sections. They were treated
with chondrocyte-specific primary antibody anti-aggrecan
(R&D Systems, Minneapolis, MI, USA) and anti-rabbit Alexa
Fluor 488 (Thermo Fisher Scientific, Waltham, MS, USA) as
a secondary antibody. For hADSCs, cells were cultured in
StemMACS AdipoDiff media and StemMACS OsteoDiff
media (Miltenyi Biotec, Bergisch Gladbach, Germany). The
procedure of detection was similar to that of rADSCs.
2.8. Cell Number and Viability.After immunomagnetic isola-
tion, cells were counted in a cell counter (Countess Invitrogen,
ThermoFisher Scientific, Inc., Paisley, UK). The percentage of
viability was measured by trypan blue. Each sample was mea-
sured by technical triplicates.
2.9. Growth Curves. The growth characteristics were
assessed in rADSCs isolated from both animals of different
ages and treated with CH. The same number of cells
(5 × 104 cells/well) from each sample was cultured in
duplicate in a 6-well plate. At different times (days 3, 5, and
7), cells were harvested and counted as indicated above.
These cells reached a lag phase on the 2nd-3rd days, a log
phase on the 3rd-6th days, and a plateau phase after the 7th
day (at a density of 5 × 103/cm2 in a 6-well plate).
2.10. Tissue and Cell Homogenization. Hepatic tissue from
the same animals was homogenized in 10mM N-2-hydro-
xyethylpiperazine-N ′-2-ethanesulfonic acid (HEPES),
pH7.0, and 0.2mM phenylmethylsulfonyl fluoride (PMSF)
buffer. The homogenate was centrifuged at 800×g for
10min. The supernatant was centrifuged at 12,000×g for
20min at 4°C, and the pellet was discarded. Cells were lysed
in RIPA buffer (20mM Tris-HCl, 150mM NaCl, 1mM
EDTA, 1mM EGTA, 1% NP-40, 1% sodium deoxycholate,
2.5mM sodium pyrophosphate, and 1mM sodium orthova-
nadate) containing protease inhibitors. The homogenized
cells were centrifuged at 12,000×g for 20min at 4°C, and
the supernatant was collected.
2.11. 4-Hydroxynonenal Adduct Analysis. Protein extracts
from the liver and cells were measured by enzyme-linked
immunosorbent assay (ELISA) to detect 4-hydroxynonenal
(4-HNE) adducts in the samples, following the manufacturer’s
Table 1: Basal patient characteristics.
Patients included n = 12
Age, mean ± SEM 34:3 ± 2:1 (25, 25, 29, 29, 31, 32, 34, 36, 39, 39, 45, and 48 years)
Surgery type Abdominoplasty
BMI (kg/m2) 24-29
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instructions (OxiSelect© HNE-His, Cell Biolabs, San Diego,
CA, USA).
2.12. Quantification of Differentiation. The total number of
adipose cells was counted in duplicate from each sample,
using five consistent regions within each well. Multiple fields
of view (×200 magnification) were obtained from each of
these regions, starting from the center of the well and travel-
ing out to the periphery, but not near the walls to avoid the
meniscus effect [43]. Values from these regions were aver-
aged to give the mean differentiation level for each sample
and were expressed in percentage, the control group being
100% of the adipogenic differentiation. In hADSCs, adipo-
genesis was measured by quantifying the levels of glycerol-
3-phosphate dehydrogenase (GPDH) (Sigma-Aldrich, Saint
Louis, MO, USA) by Western blot (WB) [44–46]. To assess
the levels of calcium deposit after osteogenic differentiation,
the osteoblast matrix was demineralized by the addition of
500μl of 0.6N HCl and incubated overnight at 37°C. Solu-
tions were collected and centrifuged for 5min at 250×g. Cal-
cium concentrations in the supernatants were determined
colorimetrically (QuantiChrom Calcium Assay Kit, BioAssay
Systems, Hayward, CA) according to the manufacturer’s
instructions, by measuring the absorbance at 610nm, using
a plate reader (Asys UVM340, Biochrom, Cambourne, UK).
2.13. Western Blotting. The protein content of the samples
was estimated with the DC Protein Assay Kit (Bio-Rad,
Hercules, CA, USA). Protein samples were separated by
SDS-PAGE (10% acrylamide) and transferred to the nitrocel-
lulose membrane (Bio-Rad, Hercules, CA, USA) at 120V for
1 h. The membranes were incubated with a blocking buffer
(5% dry milk in 20mM Tris-HCl, pH7.5, 500mM NaCl,
and 0.05% Tween 20) for 1 h at room temperature. Mem-
branes were incubated overnight at 4°C in a blocking solution
containing the following antibodies: eEF2 (1 : 1000), AMPKα
(1 : 1000), SIRT1 (1 : 1000) (Cell Signaling Technology,
Danvers, MA, USA), Sox2 (1 : 500), Nanog (1 : 500) (Abnova,
Taipei, Taiwan), GPDH (1 : 1000), GAPDH, β-actin, and α-
tubulin (1 : 3000) (Sigma-Aldrich, Saint Louis, MO, USA).
After incubation, the membranes were washed in 20mM
Tris-HCl, pH7.5, 500mM NaCl, and 0.05% Tween 20 and
incubated with peroxidase-conjugated anti-immunoglobulin
secondary antibodies. The proteins were visualized using
chemiluminescence reagents (Advansta, Menlo Park, CA,
USA). The bands were analyzed by densitometry using ImageJ
analysis software (NIH). GAPDH and α-tubulin were used as
loading controls. Some membranes were reused with Restore®
Western Blot Stripping Buffer (Thermo Fisher Scientific, Wal-
tham, MA, USA) following the manufacturer’s instructions.
2.14. MTS/PMS Viability Assay. Cells were cultured in a 96-
well plate at 1:5 × 104 cells/well density overnight. Then, they
were exposed to different concentrations of CH (0-120μM)
for 3 h. After treatment, the medium was removed and
washed twice with PBS. 120μl of the culture medium with
MTS/PMS (CellTiter 96, Promega, Madison, WI, USA) was
added. Two hours later, absorbance was measured in a plate
reader (λmax = 490 nm).
2.15. Statistical Analysis.Data are shown as themean ± SEM.
One-way ANOVA, followed by Tukey’s test, was used to
compare more than two groups, and Pearson’s test was used
to bivariate correlations. All analyses were performed in SPSS
21 software (IBM, Armonk, NY, USA). A value of p ≤ 0:05
was considered significant.
3. Results
3.1. Characterization of ADSCs. Mesenchymal and Tissue
Stem Cell Committee of the International Society for Cellular
Therapy (ISCT) proposed a set of standard criteria to define
this population of cells [1, 47]. These criteria are as follows:
adherence to plastic under standard culture conditions;
“in vitro” differentiation into osteoblasts, adipocytes, and
chondroblasts; specific surface antigen expression in which
95% of the cells express the antigens CD105, CD73, and
CD90.1; and absence (<3% positive) of hematopoietic lineage
antigens CD45, CD34, CD14 or CD11b, CD79a or CD19,
and HLA-DR. In the case of murine models, these criteria
have not been established yet, though many authors replicate
the criteria established for human cells [41, 48, 49]). In this
work, we confirmed that both the rat and human ADSCs
meet these criteria. Both rADSCs and hADSCs showed
adherence to the plastic and absence of cells in suspension
under standard culture conditions (Supplementary
Figures 1A and 2A, respectively).
For rADSCs, using flow cytometry, we found that 98:0
± 0:9% of the events were positive for MSC markers such
as CD29 and CD90.1. Less than 3% of all events showed
positive expression for any of the hematopoietic markers
CD11b, CD34, and CD45 (Supplementary Figure 1B). The
differentiation of rADSCs into osteoblasts, adipocytes, and
chondroblasts was analyzed in vitro. We observed the
intracellular accumulation of lipids detected by Oil Red O
staining after adipogenic differentiation; high expression of
phosphate alkaline showed osteogenic differentiation, and
positive anti-aggrecan immunofluorescence indicated
chondrogenic differentiation (Supplementary Figure 1C).
The same procedures were performed with hADSCs to
assess phenotyping and differentiation. The flow cytometry
analysis showed that the number of events in the double-
positive region for CD90/CD105 and CD90/CD73 was
99:67 ± 0:32% and 99:69 ± 0:20%, respectively. The expres-
sion of CD14, CD20, CD34, and CD45 as hematopoietic
markers was less than 0.5% (Supplementary Figure 2B). In
addition, hADSCs from patients of different ages were
differentiated into osteoblasts and adipocytes (Supplementary
Figure 2C). Taking together, these results indicate that both
the rat and human cells isolated from adipose tissue can be
considered MSCs.
3.2. Effect of Age and In Vivo CH Treatment on 4-HNE-
Protein Adduct Formation in the Liver and rADSCs. As we
reported in previous studies, age and CH treatment can
induce 4-HNE-protein adduct formation in the liver both
in vitro and in vivo [33]. To ensure that the age of the rats
we used in these experiments and CH treatment induced
LP, the levels of the 4-HNE-protein adduct were determined
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in both the liver and the rADSCs of rats of different ages and
treated with CH. In the liver, we found a significant increase
of 42% of the 4-HNE adduct in the 24-month-old group with
respect to the levels found in the 2-month-old group
(Figure 1(a)). No significant differences were found between
the other age groups. In livers from animals treated with
40mg/kg/day of CH, we found an increase of 18.7% of the 4-
HNE adduct, compared with the control group (Figure 1(b)).
In rADSCs, the increase of 4-HNE-protein adduct for-
mation was similar to that found in liver samples: 38%
increase in the 24-month-old group with respect to young
rats (Figure 1(c)). When animals were treated with CH, the
amount of adduct formation between 4-HNE and proteins
of ADSCs was slightly higher than in the liver (Figure 1(d)).
3.3. Effect of Age and In Vivo CH Treatment on the Number,
Viability, andGrowth Curve of rADSCs.We found a significant
decrease in the number of rADSCs in 9- and 24-month-old
rats with respect to the young group (Figure 2(a)). On the con-
trary, we did not find significant differences in cell viability
between these groups (Figure 2(b)).
In the case of the rats treated with 40mg/kg/day, the
number of rADSCs remained unaltered with no significant
differences between the experimental groups (Figure 2(c)).
However, when we measured the cell viability, the group
treated with 80mg/kg/day of CH showed a significant and
important loss of viability (61 ± 2:71%) (Figure 2(d)).
The growth characteristics were assessed in rADSCs. The
results showed that the proliferation of rADSCs from 24-
month-old rats slows down during the lag phase (2-3 days)
with respect to the 2- and 9-month-old groups (Figure 2(e)).
These results indicate some kind of alteration in the cellular
growth or adaptation to the culture environment of these
cells. After a few days, the culture enters a period of most
active growth similar to rADSCs obtained from younger ani-
mals. No change in the growth pattern of cultured cells was
observed in rADSCs isolated from the group treated with
40mg/kg/day of CH in comparison to the control group
(Figure 2(f)). 80mg/kg/day of the CH group was discarded
for the determination of the growth curves because this con-
centration induced a significant decrease of cell viability in
rADSCs (less than half of the cultures were viable).
3.4. Effect of Age and In Vivo CH Treatment on rADSCs’
Pluripotency and Differentiation. To determine whether age
and in vivo CH treatment affect the pluripotency of rADSCs,
we assessed the levels of Nanog and Sox2. In rADSCs, our
results showed that Nanog levels significantly decreased up
to 60% and 43% in 9- and 24-month-old rats, respectively,
compared to the control group (Figure 3(a)). Similarly, the
levels of Nanog in 2-month-old animals treated with
40mg/kg/day of CH decreased up to 63.5% with respect to
the control group (Figure 3(b)). The levels of Sox2 were only
significantly lower (33%) in the 24-month-old group with
respect to young animals (Figure 3(c)). While levels of Nanog
decrease, Sox2 levels were upregulated (46%) in ADSCs
obtained from CH-treated rats (Figure 3(d)).
We also quantified the capability of rADSCs obtained
from rats of different ages and treated with CH to differenti-
ate into adipocytes and osteoblasts when these cells are
induced to do so in vitro. Our results showed that all samples
(from 2-, 9-, and 24-month-old and CH-treated rats) were
positive for adipogenic differentiation (Supplementary
Figure 3A), as indicated by the presence of lipid vacuoles
after staining with Oil Red O. Also, the percentage of
adipocytes formed by differentiation of rADSCs decreased
as a function of the age (Figure 3(e)). Thus, rADSCs from
the 24-month-old group led to 65% fewer adipocytes than
the 2-month-old rADSCs. On the contrary, we found a
significant 39% increase in adipogenic differentiation in
CH-treated rats compared to the control group (Figure 3(f)).
Regarding osteogenic differentiation, all samples were pos-
itive to staining with NBT/BCIP after the experimental induc-
tion, which indicates the presence of alkaline phosphatase
(Supplementary Figure 3B). As to adipogenic differentiation,
the osteogenic differentiation also decreased with age. Thus,
the rADSCs obtained from the 24-month-old group had
32% less Ca2+ levels than the rADSCs obtained from the 2-
month-old group (Figure 3(g)). The group treated with CH
also showed a decrease of 38% in Ca2+ levels (Figure 3(h)).
Therefore, osteogenic differentiation decreases with both
age and CH treatment.
3.5. Effect of Age and In Vivo CH-Induced LP on eEF2,
AMPKα, and SIRT1 Levels in rADSCs. Levels of different pro-
teins have also been studied that can play a key role not only
in the stem cell biology but also in any other cells: AMPKα
and SIRT1. Because many biological actions of these two pro-
teins converge on protein synthesis, specifically in eEF2, the
levels of this protein were also included in this study.
In the rat liver, we observed a decrease in the level of eEF2
as a function of the age and after the CH treatment
(Figures 4(a) and 4(b)). These findings agree with previous
results reported from our laboratory [33–35, 50]. Thus,
eEF2 levels were significantly reduced to 48 and 20% in 9-
and 24-month-old rats, respectively, with respect to the
young group (Figure 4(a)). CH also led to a significant
decrease of 63% in the levels of eEF2 with respect to control
values (Figure 4(b)). In rADSCs, eEF2 levels did not decrease
with age but their levels increased by 44% in 24-month-old
rats in comparison to the 9-month-old group (Figure 4(c)).
However, CH treatment did not induce any change in the
eEF2 levels (Figure 4(d)).
We have also found significant changes in the hepatic
levels of AMPK during aging. There is a significant increase
in the levels of this protein in 9-month-old rats with respect
to young animals. Later, the results show a decrease of 66%
in the levels of AMPK in the 24-month-old group with
respect to 9-month-old rats (Figure 4(e)). These results agree
with previous reports indicating that AMPK decreases with
age [29, 51, 52]. Similar to aging, CH treatment decreased
the hepatic levels of AMPK by 55% (Figure 4(f)). In rADSCs,
the changes in the expression of AMPK with age were similar
to those found in the liver but no significant reduction was
observed in CH-treated rats (Figures 4(g) and 4(h)).
The levels of SIRT1 were also studied in both the rat liver
and the rADSCs. In hepatic cells, our results showed a signif-
icant decrease of 65% between the 2-month-old and 9-
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month-old groups, with no further decrease in the 24-
month-old group (Figure 4(i)). On the contrary, CH treat-
ment led to an increase in the levels of SIRT1 (Figure 4(j)).
In rADSCs, the levels of SIRT1 remain unchanged in 9-
month-old rats and rise to 86% in 24-month-old groups,
respectively, with respect to the young group (Figure 4(k)).
As in the liver, CH treatment increased the levels of SIRT1
by 46% with respect to the control group (Figure 4(l)).
3.6. Effect of Age in hADSCs. hADSCs from patients of differ-
ent ages (25 to 48 years old) were assessed to determine both
their levels of Nanog and Sox2, differentiation capabilities
into adipocytes and osteoblasts, and protein levels of eEF2,
AMPKα, and SIRT1. Our results showed that only Sox2
decreased significantly with age and no significant change
was found for Nanog (Figures 5(a) and 5(b)). In order to
make a correct comparison between humans and rats, we
should have had a wider range of human ages to include
younger and older individuals. However, if one considers
only the comparison between middle-aged and older people,
it is tempting to affirm that results are somehow similar. In
rats, the higher values of Nanog were found only in young
individuals with no significant differences between middle-
aged and aged animals (Figure 3(a)); Sox2 significantly
decreased only in very old individuals (Figure 3(c)).
In regard to the differentiation potential of hADSCs, the
results were different from those found in rADSCs. Thus,
adipogenic differentiation increased significantly with age
(Figure 5(c)), and no change in the capacity of differentiation
into osteoblasts was observed (Figure 5(d)). All hADSC sam-
ples tested showed adipocyte and osteoblast differentiation
capacity (Supplementary Figure 4).
Finally, we assessed the levels of eEF2 (Figure 5(e)),
AMPKα (Figure 5(f)), and SIRT1 (Figure 5(g)) in hADSCs
obtained from patients of different ages. As can be seen,
eEF2 levels have a significant positive correlation with
age; meanwhile, AMPKα and SIRT1 tend to decrease
during aging.
3.7. In Vitro Effect of CH on Human and Rat ADSC Viability.
We also studied the possible difference in the vulnerability of
rADSCs and hADSCs under the oxidative stress caused by
CH. Using MTS/PMS assay, we determined the in vitro
viability of the rat ADSCs (9-month-old), human (25-48 years
old) ADSCs, and HeLa cell line (as a human nonstem cell con-
trol) exposed to different concentrations of CH (0-120μM).
The results show that hADSCs were the most resistant to
CH, especially at high doses (Figure 6(a)). At a low dose of
CH (40μM), both hADSCs and rADSCs were more resistant
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Figure 1: Effect of age and in vivo CH treatment on 4-HNE-protein adduct formation in the liver and rADSCs. Quantification of 4-HNE
levels measured by ELISA in the liver (a, b) and rADSCs (c, d) obtained from 2-, 9-, and 24-month-old rats (n = 4) (a, c) and from 2-
month-old rats treated with 40mg/kg/day of CH (2mo+CH) or saline (2mo+Sal) (n = 4) (b, d). Values are the mean ð%Þ ± SEM expressed
as percentages with respect to the value of the control group (100%). One-way ANOVA followed by Tukey’s test was performed for
multiple comparisons. ∗p < 0:05 and ∗∗p < 0:01 (a, c). One-way ANOVA was performed for comparison of two groups. ∗∗p < 0:01 and ∗∗∗
p < 0:001 (b, d).






























































































Figure 2: Effect of age and in vivo CH treatment on the viability, cell number, and cell growth in rat ADSCs. Quantitative score of CD90.1-
positive cells per gram of tissue after immunomagnetic separation from 2- (n = 4), 9- (n = 4), and 24-month-old rats (n = 3) (a). Trypan blue
exclusion test of cell viability in CD90.1-positive cells after immunomagnetic separation from 2- (n = 4), 9- (n = 4), and 24-month-old rats
(n = 3) (b). Quantitative score of CD90.1-positive cells per gram of tissue after immunomagnetic separation from 2-month-old rats treated
with saline (n = 4), 40mg/kg/day of CH (n = 4), and 80mg/kg/day of CH (n = 4) (c). Trypan blue exclusion test of cell viability in CD90.1-
positive cells after immunomagnetic separation from 2-month-old rats treated with saline (n = 4), 40mg/kg/day of CH (n = 5), and
80mg/kg/day of CH (n = 5) (d). Cell growth curves of rADSCs from 2- (n = 3), 9- (n = 3), and 24-month-old rats (n = 4) (e). Cell growth
curves of rADSCs from 2-month-old rats treated with saline (n = 4) and 40mg/kg/day of CH (n = 4) (f). Values are the mean ± SEM.
One-way ANOVA followed by Tukey’s test was performed for multiple comparisons (∗∗p < 0:01 and ∗∗∗p < 0:001).
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in viability between rADSCs and HeLa cells; meanwhile,
hADSCs kept high levels of viability (59:0 ± 13:4%).
The effect of CH was also tested in vitro on hADSCs from
patients of different ages. Cells were treated with two concen-
trations of the oxidant, 80 and 120μM for 3 h. hADSCs from
P48 (48 years old) was the most sensitive sample up to 80μM
of CH (cell viability of 31:12 ± 7:49%). The viabilities of the
other samples were similar and remain unaltered
(Figure 6(b)). However, when CH concentration increased
up to 120μM, the viabilities of P29 (29 years old) and P31
(31 years old) were significantly affected, to reach a similar
value to that found in P48 (18:76 ± 5:37%) (Figure 6(c)).
4. Discussion
In this study, we investigated several aspects of stem cell biol-
ogy that are related to their capacity to proliferate, differenti-
ate, and resist oxidative stress. We have focused on different
molecular pathways that directly and indirectly drive these
biological aspects and how they can be affected by aging and
oxidative stress. The effect of aging was addressed because
an important issue in autologous SC transplant is whether
stem cell-based therapies should be restricted to certain donor
age. The successful clinical application of cell therapy depends
on the ability of stem cells to replace cells in damaged tissues,
where stem cells might have to adapt to an adverse environ-
ment, for instance, oxidative stress. High oxidative stress
contributes to general biomolecular damages resulting in an
impairment of physiological functions that takes place in both
aging and chronic age-related diseases. Moreover, uncon-
trolled oxidative stress is a hallmark of the aging process
which is associated with mitochondrial dysfunction, inhibi-
tion of autophagy, and accelerated aging [53, 54]. Oxidative
stress has also been associatedwith cellular senescence, persis-
tent inflammation, telomere erosion, and dysregulation of
intracellular metabolites that promote apoptosis [55]. Given
that stem cells need to adapt to an oxidative stress adverse
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Figure 3: Effect of age and in vivo CH treatment on the levels of Nanog and Sox2 and differentiation potential in rADSCs. Levels of Nanog (a,
b) and Sox2 (c, d) measured byWB in 2- (2mo) ((a), n = 3; (c), n = 4), 9- (9mo) (n = 4), and 24-month-old rats (24mo) (n = 3) (a, c) and in 2-
month-old rats treated with 40mg/kg/day of CH (2mo+CH) ((b), n = 5; (d), n = 4) or saline (2mo+Sal) (n = 4) (b, d). Quantification of
adipogenic differentiation by systematic counting of differentiated adipocytes (e, f) and osteogenic differentiation by spectrophotometry
detection of Ca2+ (mg/ml) concentration after osteoblast formation (g, h) of rADSCs from 2- (2mo) (n = 4), 9- (9mo) (n = 4), and 24-
month-old rats (24mo) (n = 3) (e, g) and from 2-month-old rats treated with 40mg/kg/day of CH (2mo+CH) (n = 4) or saline (2mo+Sal)
((f), n = 4; (h), n = 3) (f, h). Values are the mean ð%Þ ± SEM expressed as percentages with respect to the value of the control group
(100%). One-way ANOVA followed by Tukey’s test was performed for multiple comparisons. ∗p < 0:05 and ∗∗p < 0:01 (a, c, e, and g).
One-way ANOVA was performed for comparison of two groups. ∗p < 0:05 and ∗∗∗p < 0:001 (b, d, f, and h).
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Figure 4: Quantification of eEF2, AMPKα, and SIRT1 in rADSCs. Optical densities of eEF2, AMPKα, and SIRT1 were measured by WB in
the liver (a, b, e, f, i, and j) and rADSCs (c, d, g, h, k, and l) from 2- (2mo, n = 3), 9- (9mo, n = 4), and 24-month-old rats (24mo, n = 3) (a, c, e,
g, i, and k) and from 2-month-old rats treated with 40mg/kg/day of CH (2mo+CH, n = 4, except for (l), n = 5) or saline (2mo+Sal, n = 4,
except for (l), n = 3) (b, d, f, h, j, and l). Values are the mean ð%Þ ± SEM expressed as percentages with respect to the value of the control
group (100%). One-way ANOVA followed by Tukey’s test was performed for multiple comparisons. ∗p < 0:05 and ∗∗∗p < 0:001 (a, b, e, f,
i, and j). One-way ANOVA was performed for comparison of two groups. ∗p < 0:05 (c, d, k, and l).

















































































12 Oxidative Medicine and Cellular Longevity
capacity is associated with accelerated aging by decreasing
proliferation and increasing senescence and apoptosis, here
we discussed how aging and oxidative stress induced by CH
can affect the ADSCs’ therapeutic capacity and/or their sur-
vival capabilities in the site of transplantation.
The present study has been carried out in ADSCs
obtained from humans and rats of different ages. ADSCs
were obtained from SVF of lipoaspirates digested enzymati-
cally followed by immunomagnetic isolation with antibodies
conjugated to microbeads [39, 40, 49, 56]. This isolation
method allows us to obtain a more homogeneous MSC pop-
ulation (Supplementary Figures 1B and 2B) than other
methods based on SVF seeding [41, 57]. This is because
SVF is like a soup that contains different cell populations
with several types of cells with multipotent capacity [2]. In
the human bone marrow, the percentage of MSC CD271+ is
around 1.16% of total SVF cell populations [58]. In
lipoaspirates, the percentage can vary. On average, starting
from 300ml of lipoaspirate, we obtained 1 × 107 cells in the
SVF and only around 0:75‐1:25 × 105 CD271+ cells (0.75-
1.25%) were seeded onto T25 flasks. In the case of rats, the
percentage of CD90.1+ cells obtained in SVF was a bit
higher (2-3%). We cannot ensure that these differences are
related to different species or to the fact that we used
different markers for immunomagnetic separation.
To understand the influence of oxidative stress on MSCs,
we performed both in vivo (rADSCs) and in vitro (hADSCs)
studies. We used CH as an experimental model of oxidative
stress, which increases lipid peroxidation when it is injected
in vivo and ex vivo or added to cell culture [11, 33–35, 59].
It has been reported that 4-HNE levels increase with age
and after CH treatment both in vitro and in vivo in a dose-
dependent manner in the liver [33]. The measurement of
hepatic 4-HNE is used in the present study as a positive con-
trol of the CH treatment. We observe that 40mg/kg/day
treatment produced a similar increase in the levels of 4-
HNE-protein adducts in both the stem and hepatic rat cells
(Figure 1). This result suggests that rADSCs are affected by
oxidative stress, in this case by lipid peroxidation, like any
other somatic cells, probably because the mechanisms
involved in preventing ROS damage are similar.
Oxidative stress affected not only the cellular viability but
also the number of MSCs present in adipose tissue. It has
been described that the number of cells and the proliferative
and differentiation capacities of ADSCs decrease with age in
different species [60–62]. In our case, there is a considerable
decrease in the number of rADSCs with age (Figure 2(a)),
which is evident in adult age. However, viability is not
affected (Figure 2(b)). This indicates that a lower number of
MSCs are present in old adipose tissue but the viability of
the remaining cells is similar. According to this, and in order
to regenerate tissue with cell therapy, a higher amount of
adipose tissue should be used to get a high number of cells
if the donor is older.
Contrary to what is observed in aging, in vivo treatment
with CH did not affect the number of cells per gram of
𝛼TUB
eEF2




















































Figure 5: Effect of age in hADSCs. The pluripotency factors Nanog (a) and Sox2 (b) were measured in hADSCs byWB as well as the levels of
GPDH to determine adipogenesis (c). For osteogenesis assessment, the levels of Ca2+ (mg/ml) was measured by spectrophotometry at 610 nm
(d). Optical densities of eEF2 (e), AMPKα (f), and SIRT1 (g) were measured by WB. Results are expressed as optical density (OD) after
normalization with loading control protein OD values. Correlation analysis (Pearson’s r test) was performed to measure the association
between the two variables.
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adipose tissue (Figure 2(c)), but it did affect the viability
(Figure 2(d)). We can speculate on the possibility that
ADSCs from young animals are capable of rapidly replacing
the stem cells that are lost either by the direct action of CH or
by the oxidative stress-induced differentiation. Under these
circumstances, the ADSC pool is composed of newly formed
cells and CH-affected cells whose viability has been affected
but not eliminated by necrosis or apoptosis. The observed
result with altered viability but not the number of cells may
be due to the fact that the separation system used in this work
(immunomagnetic isolation of CD90.1-positive cells) does
not discriminate between these two subpopulations.
The lack of concordance between the effect of age and CH
in vivo treatment on the number and viability of the cells may
be related to the exposure time to oxidative stress. In the case
of treatment with CH, oxidative stress exposure can be con-
sidered short to affect the number of stem cells in relation
to the persistent/continuous exposure to oxidative stress over
the life span. This points in the direction that it would be con-
































































































Figure 6: Effect of age and in vitro CH treatment on human and rat ADSC viability. In vitroMTS/PMS viability assessment of the hADSCs,
rADSCs, and HeLa cell line (as a human nonstem cell control) under different concentrations of CH (0-120μM) (n = 5) (a). In vitro
MTS/PMS viability assessment of hADSCs from patients of different ages (29-48 years old) treated with 80 μM (b) and 120 μM (c) of CH
(n = 8 technical replicates from each age). Statistical analysis: values are the mean ± SEM. One-way ANOVA followed by Tukey’s test was
performed for multiple comparisons. ∗∗p < 0:01 and ∗∗∗p < 0:001 (hADSCs vs. HeLa); ##p < 0:01 and ###p < 0:001 (hADSCs vs. rADSCs);
and ¥¥¥p < 0:001 (rADSCs vs. HeLa) (a). ∗∗p < 0:01 (between ages).
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donor before a cell therapy strategy is being considered. Also,
a higher amount of adipose tissue should be used to get a
higher number of cells if the donor is older or cells are
isolated from an oxidative stress environment before a cell
therapy strategy is being considered.
It is also important to highlight the results shown in
Figure 2(e) on the rADSC growth curves once they are
cultured. The results show that older donor cells seem to
have more difficulty adapting to the culture conditions, but
finally, they end up growing at the same speed as the
rADSCs from younger donors. This result suggests that it
will take longer to get the therapeutic effects when using
ADSCs from older donors.
In this study, we also investigated the age-related changes
in some molecules responsible for SC proliferation and dif-
ferentiation. Within this group, the transcription factors
Nanog and Sox2 are crucial for the efficient maintenance of
pluripotent cell identity [23, 63, 64]. We hypothesize that
both aging and CH treatment can modify the expression of
pluripotency factors and that could have consequences in
the cell fate differentiation. In hADSCs, our results show that
the expression of Nanog remains unchanged along with the
age of the donors but the Sox2 level decreased significantly
(Figures 5(a) and 5(b)). In rats, the same change was
observed in Sox2 expression but Nanog levels were also
affected during aging (Figure 3). In principle, these results
may appear different with respect to human cells. However,
it is necessary to bear in mind that the age range used in
the human study does not include individuals as young or
as old as in the group of rats, where no additional changes
are observed in the expression of Nanog after 9 months
(Figure 3(a)). These results agree with a previous report
showing that in human bone marrow-derived mesenchymal
stromal cells, Nanog expression correlation with age was
not statistically significant either [16]. That supports the idea
that Nanog is only upregulated in young cells, where it not
only can be considered a youth indicator but also can reverse
the senescence in stem cells [22, 65]. To confirm this, more
studies are necessary with hADSCs from younger patients.
In addition to the study of the levels of these relevant
pluripotency transcription factors, we also evaluated the
effect of aging on human ADSCs’ potentiality to differentiate
into adipocytes and osteoblasts. The results show that the
potentiality to differentiate into adipocytes is promoted
(Figure 5(c)). These results show some similarities between
the effect of aging in humans and the effect of CH in rats
(Figure 3(f)) since both situations increase the adipogenic
differentiation. In addition, oxidative stress also affected
osteogenesis. Taken together, these results suggest that
oxidative stress could be responsible for the changes in the
differentiation capacity observed in aging, which would lead
to a decrease in the pool of MSCs available for regenerative
purposes. Obviously, the pathways that regulate differentia-
tion are complex [66] and, probably, are specific to each spe-
cies and are modulated by several metabolic conditions.
Thus, in rats, both Sox2 and Nanog expression decreased
with age, concomitantly to the decline of osteogenic and adi-
pogenic differentiation. In any case, special care must be
taken when trying to extrapolate results from murine models
to humans. However, we cannot forget that those results
should be interpreted having in mind the limitation of this
study regarding the sampling number and the range of age
in hADSCs.
When rats were treated with CH, the levels of Nanog
decreased but those of Sox2 increased (Figure 3). These
changes were concomitant to both the increase in the poten-
tiality to differentiating into adipocytes and the decline in
osteoblasts. This agrees with previous reports where the
increase of Sox2 induces or stimulates adipogenic differenti-
ation when Nanog levels are low, which is necessary for stem
cell differentiation [23, 67]. Park et al. (2012) observed that
oxidative stress increased the levels of Sox2 and Oct4, but
they did not mention any reference to Nanog. Ectopic
expression of Nanog maintained the stemness state [22, 65]
and inhibited adipogenesis [68]. The increment of Sox2 by
CH could be related to high levels of SIRT1 (Figure 4(l)).
By promoting Sox2 deacetylation, SIRT1 would avoid its
degradation mediated by the proteasome [69, 70]. This incre-
ment poses a problem in cell differentiation, because the
more the pluripotent capacity, the more sensitive it would
have to be to differentiate into adipocytes [23, 69, 70]. That
suggests that young rADSCs from animals treated with CH
in vivo tend to differentiate into adipocytes; meanwhile, older
ones could not do it because of the low Nanog and Sox2
levels. However, other authors suggest that cells with high
levels of Sox2 inhibit both adipogenic and osteogenic differ-
entiation [71]. We suggest that Sox2 inhibits both adipogenic
and osteogenic differentiation in the presence of Nanog [63,
67]. Nanog maintains the self-renewal state through Oct4-
Sox2-Nanog transcription factor regulation [63] and also
under certain conditions such as lipid peroxidation-
mediated caspase-3 activation [72], which would promote
Nanog destabilization [73], destroying the self-renewal state
and leaving Sox2 free to induce the differentiation process.
In addition to studying aspects related to the mecha-
nisms of pluripotency and differentiation of the ADSCs,
in this work, we have determined levels of other proteins
that can play an important role in their cell biology and
aging. These proteins are AMPK, SIRT1, and eEF2, which
are widely regarded as critical regulators of a wide variety
of cellular processes.
AMPK is a sensor of cellular energy status, a major
inducer of autophagy and stress response [26]. It has been
described that transitory AMPK activation would promote
cell survival pathways preferentially, whereas sustained
AMPK activation would trigger cell death [74]. AMPK also
plays an important role in MSC differentiation, promoting
osteogenic differentiation and suppressing adipogenic differ-
entiation [69].
In hADSCs, our results show a significant decrease in
levels of AMPK with age (Figure 5(f)). This decrease should
be considered together with the changes in eEF2. In order
to keep an active protein synthesis under a specific metabolic
situation, the AMPK activity must be reduced. However, low
levels of AMPK in ADSCs during aging could affect its
homeostasis and the ability to respond to oxidative stress
injury, not only in their original niche but also after they have
been transplanted into the injured site. In addition,
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considering the role of this enzyme in the differentiation of
stem cells, the decrease in AMPK levels with age may con-
tribute to the increased potentiality to differentiate into the
adipocytes observed with age [75, 76].
A similar decline was observed in the expression of
AMPK in rADSCs from ages 9 to 24 months (Figure 4(g)).
The same changes were observed in the liver (Figure 4(e)).
Recent studies have shown that AMPK activation, in
response to various stimuli, such as exercise and muscle con-
traction, gradually declines during aging [77]. Although
mechanisms underlying this have not been elucidated, it is
possible that the age-related increased chronic inflammation
levels suppress AMPK activation in aged tissues [78].
It is noteworthy that CH treatment only affected the
expression of hepatic AMPK but not in rADSCs. This result
may be related to what has previously been mentioned: the
effects of oxidative stress depend on whether it is transient
or more permanent. Also, it may be related to the functions
of the AMPK being tissue-specific as has been previously
described [79].
In regard to the levels of eEF2, our results show that aging
and oxidative stress decrease the levels of eEF2 in the liver.
This most likely affects the global protein synthesis in that
tissue. However, eEF2 levels of both rADSCs and hADSCs
increase with age (Figures 4(c) and 5(e)). It is possible that
eEF2 is protected in some way so that protein synthesis in
ADSCs can take place under conditions where optimal func-
tions are compromised, such as oxidative damage, and thus
contribute to tissue repair. These results show once more
the different biology of SCs in comparison to other cells since
these cells must work under harmful conditions, which is
common in damaged tissues.
Protein synthesis is a process that consumes a large
amount of energy and therefore is inhibited in the conditions
where energy is limited to conserve cellular ATP so that the
ATP is used for repair and recycling of cellular components.
AMPK inhibits cap-dependent translation during both the
initiation and elongation steps by indirectly inhibiting
mTORC1. Furthermore, AMPK directly inhibits transla-
tional elongation by phosphorylating and activating eEF2K,
which phosphorylates and inhibits eEF2 [80]. However, the
expression of those genes involved in cell repair and survival
is also required during energy stress [81]. Interestingly,
AMPK can perform these functions by switching translation
from cap-dependent to cap-independent mechanisms; thus,
global synthesis is inhibited but IRES-mediated synthesis is
activated [82]. This type of synthesis is less dependent on
an initiator factor and is activated under cellular stress condi-
tions. eEF2 participates actively in both global and IRES-
mediated synthesis. In order to participate in one or the
other, it is necessary that certain modifications occur in its
molecule. Maybe this is the reason why several regulatory
mechanisms converge in their molecule. So, it makes sense
that the levels of AMPK and eEF2 are opposite under condi-
tions where cellular biology is challenged, as we show in
ADSCs of different ages in rats and humans. Some reports
have shown that MSCs synthesize fewer amounts of proteins
than other cells because they are quiescent most of the time
[83]. Supposedly, MSCs should be more active during aging
where errors and molecular damages accumulate. In this
hypothetical situation and in the case MSCs are not affected,
their protein synthesis machinery should be activated to
carry out the maintenance, repair, or differentiation process.
According to this, our results show that old organisms have
higher levels of eEF2. However, the final restorative effect
cannot be correctly performed probably due to the decline
of pluripotency factors. The fact that these results were not
seen in rats treated with CH can perhaps be due to the treat-
ment no longer being enough or to the fact that both proteins
have different specific protection mechanisms providing
these cells with the ability to work under adverse conditions.
The levels of SIRT1 were also studied in this work. SIRT1
is another class of protective enzymes that play an important
role in cellular metabolism, health, and aging. Although it is
clear that SIRT1 is modulated by oxidative stress, the molec-
ular mechanisms are not well understood [84, 85]. It has been
suggested that SIRT1 deacetylates FOXO1 and FOXO3 and
increases the cellular resistance to oxidative stress [86]. Also,
in adult mouse hearts, SIRT1 was significantly upregulated
(4-fold) in response to oxidative stress (paraquat injection).
Similarly, a 3-fold increase in SIRT1 levels was observed in
old versus young monkey hearts [87]. Our results agree with
these studies, because CH treatment increased the levels of
SIRT1 in the liver and rADSCs. However, it has been pro-
posed that oxidative stress induces SIRT1 expression as a
compensatory mechanism, while harsh or prolonged oxidant
conditions result in dysfunctional modified SIRT1 more
prone to degradation by the proteasome. This could explain
why levels of SIRT1 in rADSCs and hADSCs decrease with
age (Figures 4(i) and 5(g)). In addition, SIRT1 plays an
important role in MSC differentiation. SIRT1 is negatively
correlated with adipogenesis and reduction of bone mass so
that SIRT1 favors MSC differentiation toward osteoblast lin-
eage at the expense of adipocyte lineage [69, 88]. Therefore,
the decrease in SIRT1, along with the decrease in AMPK
levels observed with age, may contribute to the increase in
ADSCs’ potentiality to differentiate into adipocytes observed
in hADSCs with age in our study.
The results also show a different vulnerability of rADSCs
and hADSCs when subjected to oxidative stress response
in vitro. Comparing the cellular viability after CH treatment,
we observed that hADSCs are more resistant than those
isolated from rats and other cell types such as HeLa
(Figure 6(a)). This result agrees with other authors’ results
[89–91]. It makes sense that ADSCs’ behavior is different
from other somatic cells so that they can resist harmful
events and induce their regenerative functions, at least within
certain limits that do not affect their own survival. Further
studies would be necessary to investigate whether ADSCs
have extra resistance to cope with oxidative stress and/or
high levels of 4-HNE in relation to other somatic cells.
Another important aspect is that hADSCs are more resistant
than rADSCs. It could be possible that hADSCs have higher
biochemical robustness than ADSCs from other species with
shorter life span potential as it has been described by Cutler
[92]. When we measure the cellular viability in hADSCs of
different ages, the results show that the viability is sensitive
to changes in the oxidative environment (Figures 6(b) and
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6(c)). These results suggested that not all hADSCs had the
same resistance to lipid peroxidation. These results must
be considered preliminary due to the sampling number
limitation. Further studies are required to profound in the
correlation between age and oxidative resistance. Nonethe-
less, this result anticipates that an antioxidant treatment
should be considered a potential coadjutant treatment to
cell-based therapies.
Our findings conclude that before performing a cell ther-
apy with ADSCs, several biochemical parameters should be
assessed on these cells. Not only the number of cells and via-
bility are important but also other determinations such as
oxidative stress status or differentiation capacity of the cells
should be assessed. This would allow more information on
the biochemical robustness of the injected cells and help to
predict the therapeutic result, especially in elder patients,
where probably ADSCs do not carry out their biological
functions in an optimal way.
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Supplementary Materials
Supplementary Figure 1: rat adipose-derived stem cell char-
acterization. Cell culture images of adherent rat ADSCs and
obtained after immunomagnetic isolation using CD90.1
(A). Flow cytometry analysis expressed a high percentage of
CD29/CD90.1 markers (98:0 ± 0:9%) and low expression of
CD11b/CD34/CD45 markers (<3%) in rADSCs (B). rADSCs
were differentiated into adipocytes (Oil Red O staining),
osteoblasts (alkaline phosphatase staining), and chondro-
blasts (immunocytofluorescence of anti-aggrecan) (C). Scale
bar = 50 μm. Supplementary Figure 2: human adipose-
derived stem cell characterization. Cell culture images of
adherent human ADSCs obtained after immunomagnetic iso-
lation using CD271 (A). Flow cytometry analysis expressed a
high percentage of CD90/CD105 (99:67 ± 0:32%) and
CD90/CD73 (99:69 ± 0:2%) markers and low expression of
CD14/CD20/CD34/CD45 (<0.5%) in hADSCs (B). hADSCs
obtained from patients of different ages (25 and 48 years
old) were differentiated into osteoblasts and adipocytes,
which were detected by alkaline phosphatase and Oil Red O
staining, respectively (C). Scale bar = 50μm. Supplementary
Figure 3: rat adipose-derived stem cell adipogenic/osteogenic
differentiation. Images from adipocytes pre- and poststained
with Oil Red O (A) and osteoblasts stained with NBT/BCIP
substrate (B) after differentiation induction of ADSCs from
2-, 9-, and 24-month-old rats and from 2-month-old rats
treated with 40mg/kg/day of CH or saline. Scale bar = 50 μ
m. Supplementary Figure 4: human adipose-derived stem cell
adipogenic/osteogenic differentiation. hADSCs obtained from
patients of different ages (25-48 years old) were differentiated
into osteoblasts and adipocytes, which were detected by alka-
line phosphatase or visual vacuole confirmation (sometimes
with Oil Red O staining, depending on the availability of the
cells to perform all experiments). Note that not all samples
were stained with Oil Red O dye because those implied to per-
form technical duplicates, which sometimes were impossible
to the low number of cells available to perform all the exper-
iments. Scale bar = 50 μm. (Supplementary Materials)
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